STOCK TITAN
  1. Home
  2. News
  3. MBIO

Mustang Bio, Inc. - MBIO STOCK NEWS

Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.

Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company and a subsidiary of Fortress Biotech, Inc. The company is dedicated to developing and commercializing innovative cancer immunotherapy products that harness the patient's own immune system to target and eradicate cancer cells. Mustang Bio’s approach involves acquiring the rights to cutting-edge technologies through licensing or ownership, funding their research and development, and then either out-licensing or bringing these technologies to market.

Mustang Bio has established strategic partnerships with notable institutions, including the City of Hope National Medical Center (COH) and the Fred Hutchinson Cancer Research Center. These collaborations focus on developing advanced Chimeric Antigen Receptor (CAR) engineered T cell (CAR T) therapies for various cancers.

Among Mustang’s core projects, their key programs are in Phase 1 clinical trials at COH. The MB-101 program is aimed at treating brain cancer, while MB-102 is being developed as a therapeutic agent for acute myeloid leukemia. Additionally, Mustang Bio is concentrating on gene therapies for rare genetic disorders, CAR T therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Recently, Mustang Bio has reported positive interim data from their multicenter Phase 1/2 clinical trial, showcasing a favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients. For more detailed insights, visit the 65th ASH Annual Meeting and Exposition website.

For further information and ongoing updates about Mustang Bio, you can reach them through the following contacts:

  • Jaclyn Jaffe and Nicole McCloskey - Mustang Bio, Inc., (781) 652-4500, ir@mustangbio.com
  • Tony Plohoros - Media Relations Contact, 6 Degrees, (908) 591-2839, tplohoros@6degreespr.com
News

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Rhea-AI Summary
Mustang Bio, Inc. announced Phase 1 clinical data published in Nature Medicine showing promising safety and clinical activity of MB-101 CAR T-cell therapy for recurrent malignant glioma, including glioblastoma. Patients achieved stable disease or better in 50%, with two partial responses and two complete responses. The therapy exhibited a 70% improvement in median overall survival compared to expected rates, with well-tolerated delivery methods and manageable adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
clinical trial
-
News

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

Rhea-AI Summary
A Phase 1 CAR T cell therapy trial at City of Hope for glioblastoma shows promising results. The trial, the largest reported for solid tumors, used CAR T cells targeting IL13Rα2. Half of the patients had stable disease for at least two months, with two partial responses and two complete responses. The therapy was well-tolerated, with a median overall survival of eight months. Patients receiving optimized doses had a median survival of 10.2 months, surpassing the expected rate for recurrent glioblastoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
clinical trial
-
News

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Rhea-AI Summary
Mustang Bio, Inc. (MBIO) announced that Manuel Litchman, M.D., President and CEO, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024, at 4:30 p.m. EST, focusing on the translation of medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
conferences
News

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary
Mustang Bio, Inc. (MBIO) announces updated encouraging safety and efficacy data from its multicenter Phase 1/2 clinical trial of MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The data showed favorable safety profile, complete response rate, and durability in treatment, with 100% of patients with follicular lymphoma achieving a complete response. Outpatient administration was found to be feasible, and MB-106 has a tolerable safety profile with no occurrence of CRS above grade 1 and no ICANS of any grade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
clinical trial
-
News

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Rhea-AI Summary
Mustang Bio, Inc. (MBIO) announced Q3 2023 financial results, including $10.3 million in cash, and recent corporate highlights. MB-106, a CD20-targeted CAR-T cell therapy, showed promising safety and efficacy results in treating B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The FDA accepted the IND application for MB-109, a combination therapy for recurrent glioblastoma and high-grade astrocytoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
earnings
-
News

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary
Mustang Bio announces positive interim data from Phase 1/2 clinical trial of MB-106, a CAR-T cell therapy for lymphoma patients. Four patients achieved complete response or very good partial response. Safety profile is favorable with no dose-limiting toxicities observed. CAR-T cell persistence is ongoing at 6 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
none
News

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary
Mustang Bio, Inc. has closed its registered direct offering, raising approximately $4.4 million in gross proceeds. The offering consisted of 2,588,236 shares of common stock at a purchase price of $1.70 per share. In addition, Mustang issued unregistered warrants to purchase up to 2,588,236 shares of common stock at an exercise price of $1.58 per share. The net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
offering
-
News

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary
Mustang Bio, Inc. has entered into a definitive agreement for the issuance and sale of 2,588,236 shares of common stock in a registered direct offering priced at $1.70 per share. The company will also issue unregistered warrants to purchase up to 2,588,236 shares of common stock. The offering is expected to close on October 30, 2023, with gross proceeds of approximately $4.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.19%
Tags
offering
-
News

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Rhea-AI Summary
Mustang Bio announces FDA acceptance of IND application for MB-109, a combination therapy for recurrent glioblastoma and high-grade astrocytoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.19%
Tags
clinical trial
News

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Rhea-AI Summary
Mustang Bio, Inc. announced participation in two investor conferences in New York City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
conferences

FAQ

What is the current stock price of Mustang Bio (MBIO)?

The current stock price of Mustang Bio (MBIO) is $0.2051 as of November 22, 2024.

What is the market cap of Mustang Bio (MBIO)?

The market cap of Mustang Bio (MBIO) is approximately 10.1M.

What is Mustang Bio, Inc.?

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapy products.

What are Mustang Bio's core areas of focus?

Mustang Bio focuses on gene therapies for rare genetic disorders, CAR T therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Who are Mustang Bio's key partners?

Mustang Bio has partnered with the City of Hope National Medical Center and the Fred Hutchinson Cancer Research Center.

What are Mustang Bio's lead programs?

Mustang Bio's lead programs include MB-101 for brain cancer and MB-102 for acute myeloid leukemia, both in Phase 1 clinical trials.

What recent achievements has Mustang Bio reported?

Mustang Bio recently reported positive interim data from their Phase 1/2 clinical trial indicating a favorable safety and efficacy profile of MB-106 in lymphoma patients.

How does Mustang Bio acquire its technologies?

Mustang Bio acquires technologies through licensing or ownership interests and funds their research and development.

What is CAR T therapy?

CAR T therapy involves engineering a patient's T cells to express a chimeric antigen receptor, enabling them to target and destroy cancer cells.

How can I contact Mustang Bio for more information?

You can contact Mustang Bio via Jaclyn Jaffe and Nicole McCloskey at (781) 652-4500 or email ir@mustangbio.com.

Where can I find more detailed updates on Mustang Bio's clinical trials?

More detailed updates on Mustang Bio's clinical trials can be found on the 65th ASH Annual Meeting and Exposition website.

Who should media inquiries be directed to?

Media inquiries should be directed to Tony Plohoros at 6 Degrees, reachable at (908) 591-2839 or tplohoros@6degreespr.com.

Stock MBIO logo
Mustang Bio, Inc.

Nasdaq:MBIO

MBIO Rankings

#5549 Ranked by Market Cap
N/A Ranked by Dividends

MBIO Stock Data

10.08M
44.18M
5.87%
1.88%
1.43%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WORCESTER